Navigation Links
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
Date:10/22/2008

CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities.

(PRWEB) October 22, 2008 -- Although HIV and AIDS are substantially more treatable now than during the height of the AIDS epidemic in the 1980s, numerous challenges still face AIDS and HIV patients and AIDS researchers. One major concern is that drug-resistant strains of HIV are emerging globally, but there is hope that Cytolin, a first-in-class AIDS and HIV treatment from CytoDyn, Inc., can help address this problem.

A new clinical trial to reinvestigate dosing specifications for Cytolin will be conducted in San Francisco, California, by Dr. Jay Lalezari, a leading AIDS researcher. The study will be managed by New York City-based Target Health, Inc., which CytoDyn, Inc. has retained to serve as its contract research organization for the project.

Cytolin is based on a decade of progress in immunology. Community physicians used the drug experimentally at the height of the AIDS epidemic to rescue patients when no effective antiviral treatments had yet been approved for people with AIDS.

"We're excited about the progress we've made in preparing for the next clinical trial of Cytolin," explains Dr. Nadar Pourhassan, Chief Operating Officer of CytoDyn, Inc. "We should soon be prepared to show those unfamiliar with a decade of progress in immunology that science has the solution to multi-drug resistance in HIV/AIDS and, perhaps, other infectious diseases."

Cytolin is a unique treatment for AIDS because it utilizes the immune systems of its users to control HIV infection. Strong immune systems typically control all viruses regardless of their subspecies, which suggests the potential for Cytolin to serve as an effective therapy for HIV/AIDS patients who are failing antiretroviral treatment. The drug may also help suppress drug resistant forms of HIV when used in conjunction with a successfu antiretroviral treatment for AIDS.

Allen D. Allen, Chief Executive Officer of CytoDyn, Inc., says the company philosophy is to maintain complete transparency in its operations. Visitors to CytoDyn.com can view the Company's financial records, share price, and a summary that explains the science behind Cytolin with key references to the literature.

"An enduring recovery of the global economy depends upon capitalists ending their love affair with smoke-and-mirrors, and investing in reality instead of perceptions," says Allen D. Allen, Chief Executive Officer of CytoDyn, Inc. "Unfortunately, innumeracy has to end first, and we hope to contribute to some progress in that regard."

In addition to the upcoming trial of Cytolin, CytoDyn, Inc. is announcing the relocation of its offices to 1511 Third St., Santa Fe, New Mexico. The expanded offices will accommodate new staff members who will be bringing the company's periodic filings up to date.

To learn more about CytoDyn, Inc., the upcoming clinical trials for Cytolin and how Cytolin may be used as an adjunct for antiretroviral treatments for AIDS, visit CytoDyn.com.

Disclaimer: This press release contains forward-looking statements that are not historical facts. CytoDyn's management makes forward-looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and projections and involve a number of risks and uncertainties, including but not limited to, the failure of preliminary results from clinical studies to reflect the results from more comprehensive studies. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all the factors that could cause actual results to differ materially from those estimated by CytoDyn. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements.

About CytoDyn, Inc.:
CytoDyn, Inc. is a drug manufacturing firm specializing in new, novel forms of AIDS and HIV treatment drugs. The company is best known for Cytolin, a drug that represents major advances in the treatment of HIV/AIDS. Cytolin offers an alternative by using the immune systems of those suffering from HIV/AIDS, in contrast to using antiretroviral agents to suppress the infection.

###

Read the full story at http://www.prweb.com/releases/Cytolin/clinical-trial/prweb1501134.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Gilbert Hospital Prepares for Flu Season
2. American Red Cross Prepares for Tropical Storm Fay in Florida
3. New Anti-Cellulite Treatment Prepares Women for Falls Short Skirts
4. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
5. First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
6. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
7. New Anti-Cellulite Treatment Prepares Women for Warmer Weather
8. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
9. Penn Foster Prepares Students to Meet Healthcare Employment Needs
10. Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... VisualSP has ... sustainably. Until recently, the only option for on-premises installation of its Help System for ... required to install the system into the entire tenant. , The company recently ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies announced ... address the resolution to globally reduce the harmful use of alcohol set forth ... and TTB approved ingredients that when infused into alcohol, renders the alcohol liver ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty ... year ended December 31, 2016 after market close ... being released later than the previous fiscal year,s ... operations and balances of Apicore from the acquisition ... filing date meets TSX Venture Exchange listed company ...
(Date:3/28/2017)... 28, 2017 The global emerging cancer diagnostics ... 13.45% from 2016 to 2023 and reach a figure ... Cancer is a chronic disease and is affecting a ... diagnostics market. This report is focused on emerging cancer ... growth is propelled due to factors such as: increasing ...
(Date:3/28/2017)... SPRING, Md. , March 28, 2017 /PRNewswire-USNewswire/ ... approved Dupixent (dupilumab) injection to treat adults with ... patients whose eczema is not controlled adequately by ... are not advisable. Dupixent can be used with ... of Dupixent demonstrates our commitment to approving new ...
Breaking Medicine Technology: